Black Myrobalan (
- 1Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
- 2Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; Corresponding author.
Abstract
Myrobalan or Haritaki ( Terminalia chebula Retz. ) has been integrated into Ayurvedic, Unani, and even Tibetan medicine systems for over 2000 years. The “King of Medicines” has traditionally been used for diverse ailments such as digestive issues, wound healing, and general body strengthening. Now, modern medicine is focusing on the myrobalan's potential neuroprotective properties and its use in Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS) neurodegenerative disorders. These ailments are characterized by some combination of enduring oxidative damage, mitochondrial dysfunction, neuroinflammation, irregular protein aggregation, and progressive neuron cell death. Most of the current treatment options revolve around addressing the symptoms of the diseases, which is insufficient as the underlying disease continues to progress. There is an urgent need to devise therapies that work simultaneously on multiple disease pathways. Some of the noted secondary metabolites in T. chebula include hydrolyzable tannins like chebulinic and chebulagic acid as well as corilagin. Others occur as phenolic acids such as gallic and ellagic acid and flavonoids quercetin and kaempferol. Moreover, glycosides, sterols, and a wide range of alkaloids are also present. A number of these compounds are known to possess multifunctional biological properties like scavenging ROS, activating Nrf2/ARE signaling, downregulating pro-inflammatory mediators through blockade of NF-κB, and exerting protective effects on the mitochondria, as well as modulating apoptosis via Bcl-2 and caspases. T. chebula extracts and some isolated compounds have also been shown to improve cognitive function, reduce neuroinflammation, and protect dopaminergic neurons, and ameliorate neurotoxic effects of amyloid-β or α-synuclein through in vitro and in vivo animal studies. A review of the contributions from the phytochemistry, mechanism of action, preclinical, translational, and adjunctive applications of Terminalia chebula in neurodegenerative disease therapy is presented here.
Related
- Minocycline-induced black bone disease in shoulder arthroscopy: a case report
- An Epidemiological Study of the Impact of Doula Care on Black Birth Outcomes in Baltimore, Maryland
- Occupational Noise-Induced Hearing Loss in Indian Black Tea-Processing Factories: Assessing the Prevalence and Associated Factors of an Overlooked Problem
- Age differences in opioid overdose risk factors among Black men: A brief report
- Allostatic Load Measurement and Cognitive Function Among Midlife and Older Black and White Adults in the Health and Retirement Study
BibTeX
@article{ghiasvand2026black,
title = {{Black Myrobalan (}},
author = {Kianoush Ghiasvand and Gholam Hossein Meftahi},
journal = {Biochemistry and Biophysics Reports},
year = {2026},
month = oct,
doi = {10.1016/j.bbrep.2026.102850},
url = {https://doi.org/10.1016/j.bbrep.2026.102850},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Black Myrobalan (
AU - Kianoush Ghiasvand
AU - Gholam Hossein Meftahi
PY - 2026
DA - 2026/10/24
JO - Biochemistry and Biophysics Reports
DO - 10.1016/j.bbrep.2026.102850
UR - https://doi.org/10.1016/j.bbrep.2026.102850
AB - Myrobalan or Haritaki ( Terminalia chebula Retz. ) has been integrated into Ayurvedic, Unani, and even Tibetan medicine systems for over 2000 years. The “King of Medicines” has traditionally been used for diverse ailments such as digestive issues, wound healing, and general body strengthening. Now, modern medicine is focusing on the myrobalan's potential neuroprotective properties and its use in Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS) neurodegenerative disorders. These ailments are characterized by some combination of enduring oxidative damage, mitochondrial dysfunction, neuroinflammation, irregular protein aggregation, and progressive neuron cell death. Most of the current treatment options revolve around addressing the symptoms of the diseases, which is insufficient as the underlying disease continues to progress. There is an urgent need to devise therapies that work simultaneously on multiple disease pathways. Some of the noted secondary metabolites in T. chebula include hydrolyzable tannins like chebulinic and chebulagic acid as well as corilagin. Others occur as phenolic acids such as gallic and ellagic acid and flavonoids quercetin and kaempferol. Moreover, glycosides, sterols, and a wide range of alkaloids are also present. A number of these compounds are known to possess multifunctional biological properties like scavenging ROS, activating Nrf2/ARE signaling, downregulating pro-inflammatory mediators through blockade of NF-κB, and exerting protective effects on the mitochondria, as well as modulating apoptosis via Bcl-2 and caspases. T. chebula extracts and some isolated compounds have also been shown to improve cognitive function, reduce neuroinflammation, and protect dopaminergic neurons, and ameliorate neurotoxic effects of amyloid-β or α-synuclein through in vitro and in vivo animal studies. A review of the contributions from the phytochemistry, mechanism of action, preclinical, translational, and adjunctive applications of Terminalia chebula in neurodegenerative disease therapy is presented here.
SN - 2405-5808
ER -